NLP · 3-line summary

AI Articles & Report Summaries

Expert articles and reports as a 3-line summary + takeaway

All Industrials Big Tech Macro Financials Consumer Energy Bio Semis Battery

BioLive Wire · AI-collected

Basilea Raises 2026 Profit Outlook on Cresemba Sales Growth

Swiss pharmaceutical company Basilea raised its 2026 profit outlook, citing sales growth of its antifungal drug Cresemba, according to an Investing.com report.

Published Aug 18Source: Investing.com ↗

BioLive Wire · AI-collected

Cochlear FY Profit Drops 22% but Exceeds Forecasts

Medical device maker Cochlear reported a 22% drop in full-year profit, though the results exceeded market forecasts, according to an Investing.com report.

Published Aug 18Source: Investing.com ↗

BioLive Wire · AI-collected

Argenx Shares Jump After Positive Phase 3 Results in Autoimmune Myositis Trial

Argenx shares jumped after the company reported positive Phase 3 results in an autoimmune myositis clinical trial, according to an Investing.com report.

Published Aug 17Source: Investing.com ↗

BioLive Wire · AI-collected

AstraZeneca Scraps Late-Stage Lung Cancer Trial After Data Setback

AstraZeneca scrapped a late-stage lung cancer clinical trial after a data setback, according to an Investing.com report.

Published Aug 17Source: Investing.com ↗

BioLive Wire · AI-collected

Sandoz to Pay Up to $77 Million for Three Biosimilar Drug Rights From Shanghai Henlius Biotech

Sandoz agreed to pay up to $77 million for the rights to three biosimilar drugs from Shanghai Henlius Biotech, according to an Investing.com report.

Published Aug 17Source: Investing.com ↗

BioLive Wire · AI-collected

Hutchmed Shares Rise 5% After Positive Phase III Lung Cancer Trial Results

Hutchmed shares rose 5% after the company reported positive results from a Phase III lung cancer clinical trial, according to an Investing.com report.

Published Aug 17Source: Investing.com ↗

BioLive Wire · AI-collected

AbbVie Raises 2026 Neuroscience Revenue Guidance to $12.7 Billion

AbbVie now expects its neuroscience portfolio to generate approximately $12.7 billion in revenue during 2026, raising guidance by another $100 million after a strong first half, up from $10.8 billion generated last year, according to a Yahoo Finance report.
Second-quarter neuroscience revenue climbed 20.3% year over year to $3.23 billion, with migraine drugs Ubrelvy and Qulipta rising a combined 22.6%; Q2 immunology revenue reached $8.79 billion, driven by Skyrizi and Rinvoq.
AbbVie is also developing bretisilocin, a psychedelics-based candidate for major depressive disorder acquired from Gilgamesh Pharmaceuticals, which remains in clinical trials.

Published Aug 16Source: Yahoo Finance ↗

BioLive Wire · AI-collected

Barclays Downgrades Polypeptide After Strong H1 Rally, Samsung Offer

Barclays downgraded Polypeptide following a strong first-half rally in its shares and a Samsung acquisition offer, according to an Investing.com report.

Published Aug 14Source: Investing.com ↗

BioLive Wire · AI-collected

Valneva Shares Soar to Highest Since May as EMA Validates Key Lyme Vaccine Filing

Valneva shares soared to their highest level since May after the European Medicines Agency validated a key filing for its Lyme disease vaccine, according to an Investing.com report.

Published Aug 14Source: Investing.com ↗

BioLive Wire · AI-collected

BridgeBio Shares Fall as KKR Launches Secondary Offering

BridgeBio shares fell after KKR launched a secondary offering of the company's stock, according to an Investing.com report.

Published Aug 13Source: Investing.com ↗

BioLive Wire · AI-collected

Zoetis Gets US FDA Emergency Use Nod for Screwworm Treatment in Dogs

Zoetis received US FDA emergency use authorization for a treatment for screwworm in dogs, according to an Investing.com report.

Published Aug 13Source: Investing.com ↗

BioLive Wire · AI-collected

Lawsuit Against Bristol Myers Over Delayed Cancer Drug Is Revived

A lawsuit against Bristol Myers Squibb over a delayed cancer drug was revived, according to an Investing.com report.

Published Aug 13Source: Investing.com ↗

BioLive Wire · AI-collected

As Hims Prepares for Peptides Launch, Wall Street Cautious on Prospects This Year

As Hims & Hers prepares to launch peptide products, Wall Street remains cautious about its prospects this year, according to an Investing.com report.

Published Aug 12Source: Investing.com ↗

BioLive Wire · AI-collected

Cencora Says Walgreens Volumes Shift, Reaffirms Guidance as Shares Sink

Cencora said Walgreens-related volumes are shifting and reaffirmed its financial guidance, though shares sank on the news, according to an Investing.com report.

Published Aug 12Source: Investing.com ↗

BioLive Wire · AI-collected

Eli Lilly Sues Six Companies Over Alleged Illegal Sales of Experimental Obesity Drug Retatrutide

Eli Lilly filed lawsuits against six companies over alleged illegal sales of its experimental obesity drug retatrutide, which has not yet received regulatory approval, according to an Investing.com report.

Published Aug 12Source: Investing.com ↗

BioLive Wire · AI-collected

Glenmark's US Unit Settles Humana Antitrust Case for $15.3 Million

Glenmark's US unit settled an antitrust case with Humana for $15.3 million, according to an Investing.com report.

Published Aug 12Source: Investing.com ↗

BioLive Wire · AI-collected

Vogenx Prices IPO at $13 Per Share, Raising $81.3 Million

Vogenx priced its IPO at $13 per share, raising $81.3 million, according to an Investing.com report.

Published Aug 11Source: Investing.com ↗

BioLive Wire · AI-collected

Factbox: Global Drugmakers Invest Billions to Boost US Presence

Global pharmaceutical companies are investing billions of dollars to boost their US presence, according to an Investing.com factbox report.

Published Aug 11Source: Investing.com ↗

BioLive Wire · AI-collected

AdaptHealth to Sell $600 Million Diabetes Business to Cardinal Health

AdaptHealth is selling its roughly $600 million diabetes business to Cardinal Health and exiting certain e-commerce and drop-ship operations to focus on sleep, respiratory and home medical equipment.
The company reported 16% second-quarter revenue growth, though its new West Coast capitated contract faced higher-than-expected service costs from utilization and hospital-ordering issues.

Published Aug 11Source: Yahoo Finance ↗

BioLive Wire · AI-collected

Hims & Hers Raises Annual Revenue Forecast on Strong Subscriber Growth

Hims & Hers raised its annual revenue forecast, citing strong subscriber growth, according to an Investing.com report.

Published Aug 10Source: Investing.com ↗

BioLive Wire · AI-collected

Eli Lilly's Weight-Loss Pill Secures First European Nod in Britain

Eli Lilly's weight-loss pill secured its first European regulatory approval in Britain, according to an Investing.com report.

Published Aug 10Source: Investing.com ↗

BioLive Wire · AI-collected

Latigo Biotherapeutics Shares Jump 17% After Upsized IPO

Latigo Biotherapeutics shares jumped 17% after the company's upsized IPO, according to a report.

Published Aug 7Source: Investing.com ↗

BioLive Wire · AI-collected

Oxford Biomedica Cuts 2026 Revenue Guidance by 17%

Oxford Biomedica cut its 2026 revenue guidance by 17%, according to a report.

Published Aug 7Source: Investing.com ↗

BioLive Wire · AI-collected

Gedeon Richter Upgrades FY26 Profit Guidance on Vraylar Strength

Gedeon Richter upgraded its FY26 profit guidance, citing strength in Vraylar, according to a report.

Published Aug 7Source: Investing.com ↗

NLP · 3-line summary

AI Articles & Report Summaries

Expert articles and reports as a 3-line summary + takeaway

All Industrials Big Tech Macro Financials Consumer Energy Bio Semis Battery

BioLive Wire · AI-collected

Basilea Raises 2026 Profit Outlook on Cresemba Sales Growth

Swiss pharmaceutical company Basilea raised its 2026 profit outlook, citing sales growth of its antifungal drug Cresemba, according to an Investing.com report.

Published Aug 18Source: Investing.com ↗

BioLive Wire · AI-collected

Cochlear FY Profit Drops 22% but Exceeds Forecasts

Medical device maker Cochlear reported a 22% drop in full-year profit, though the results exceeded market forecasts, according to an Investing.com report.

Published Aug 18Source: Investing.com ↗

BioLive Wire · AI-collected

Argenx Shares Jump After Positive Phase 3 Results in Autoimmune Myositis Trial

Argenx shares jumped after the company reported positive Phase 3 results in an autoimmune myositis clinical trial, according to an Investing.com report.

Published Aug 17Source: Investing.com ↗

BioLive Wire · AI-collected

AstraZeneca Scraps Late-Stage Lung Cancer Trial After Data Setback

AstraZeneca scrapped a late-stage lung cancer clinical trial after a data setback, according to an Investing.com report.

Published Aug 17Source: Investing.com ↗

BioLive Wire · AI-collected

Sandoz to Pay Up to $77 Million for Three Biosimilar Drug Rights From Shanghai Henlius Biotech

Sandoz agreed to pay up to $77 million for the rights to three biosimilar drugs from Shanghai Henlius Biotech, according to an Investing.com report.

Published Aug 17Source: Investing.com ↗

BioLive Wire · AI-collected

Hutchmed Shares Rise 5% After Positive Phase III Lung Cancer Trial Results

Hutchmed shares rose 5% after the company reported positive results from a Phase III lung cancer clinical trial, according to an Investing.com report.

Published Aug 17Source: Investing.com ↗

BioLive Wire · AI-collected

AbbVie Raises 2026 Neuroscience Revenue Guidance to $12.7 Billion

AbbVie now expects its neuroscience portfolio to generate approximately $12.7 billion in revenue during 2026, raising guidance by another $100 million after a strong first half, up from $10.8 billion generated last year, according to a Yahoo Finance report.
Second-quarter neuroscience revenue climbed 20.3% year over year to $3.23 billion, with migraine drugs Ubrelvy and Qulipta rising a combined 22.6%; Q2 immunology revenue reached $8.79 billion, driven by Skyrizi and Rinvoq.
AbbVie is also developing bretisilocin, a psychedelics-based candidate for major depressive disorder acquired from Gilgamesh Pharmaceuticals, which remains in clinical trials.

Published Aug 16Source: Yahoo Finance ↗

BioLive Wire · AI-collected

Barclays Downgrades Polypeptide After Strong H1 Rally, Samsung Offer

Barclays downgraded Polypeptide following a strong first-half rally in its shares and a Samsung acquisition offer, according to an Investing.com report.

Published Aug 14Source: Investing.com ↗

BioLive Wire · AI-collected

Valneva Shares Soar to Highest Since May as EMA Validates Key Lyme Vaccine Filing

Valneva shares soared to their highest level since May after the European Medicines Agency validated a key filing for its Lyme disease vaccine, according to an Investing.com report.

Published Aug 14Source: Investing.com ↗

BioLive Wire · AI-collected

BridgeBio Shares Fall as KKR Launches Secondary Offering

BridgeBio shares fell after KKR launched a secondary offering of the company's stock, according to an Investing.com report.

Published Aug 13Source: Investing.com ↗

BioLive Wire · AI-collected

Zoetis Gets US FDA Emergency Use Nod for Screwworm Treatment in Dogs

Zoetis received US FDA emergency use authorization for a treatment for screwworm in dogs, according to an Investing.com report.

Published Aug 13Source: Investing.com ↗

BioLive Wire · AI-collected

Lawsuit Against Bristol Myers Over Delayed Cancer Drug Is Revived

A lawsuit against Bristol Myers Squibb over a delayed cancer drug was revived, according to an Investing.com report.

Published Aug 13Source: Investing.com ↗

BioLive Wire · AI-collected

As Hims Prepares for Peptides Launch, Wall Street Cautious on Prospects This Year

As Hims & Hers prepares to launch peptide products, Wall Street remains cautious about its prospects this year, according to an Investing.com report.

Published Aug 12Source: Investing.com ↗

BioLive Wire · AI-collected

Cencora Says Walgreens Volumes Shift, Reaffirms Guidance as Shares Sink

Cencora said Walgreens-related volumes are shifting and reaffirmed its financial guidance, though shares sank on the news, according to an Investing.com report.

Published Aug 12Source: Investing.com ↗

BioLive Wire · AI-collected

Eli Lilly Sues Six Companies Over Alleged Illegal Sales of Experimental Obesity Drug Retatrutide

Eli Lilly filed lawsuits against six companies over alleged illegal sales of its experimental obesity drug retatrutide, which has not yet received regulatory approval, according to an Investing.com report.

Published Aug 12Source: Investing.com ↗

BioLive Wire · AI-collected

Glenmark's US Unit Settles Humana Antitrust Case for $15.3 Million

Glenmark's US unit settled an antitrust case with Humana for $15.3 million, according to an Investing.com report.

Published Aug 12Source: Investing.com ↗

BioLive Wire · AI-collected

Vogenx Prices IPO at $13 Per Share, Raising $81.3 Million

Vogenx priced its IPO at $13 per share, raising $81.3 million, according to an Investing.com report.

Published Aug 11Source: Investing.com ↗

BioLive Wire · AI-collected

Factbox: Global Drugmakers Invest Billions to Boost US Presence

Global pharmaceutical companies are investing billions of dollars to boost their US presence, according to an Investing.com factbox report.

Published Aug 11Source: Investing.com ↗

BioLive Wire · AI-collected

AdaptHealth to Sell $600 Million Diabetes Business to Cardinal Health

AdaptHealth is selling its roughly $600 million diabetes business to Cardinal Health and exiting certain e-commerce and drop-ship operations to focus on sleep, respiratory and home medical equipment.
The company reported 16% second-quarter revenue growth, though its new West Coast capitated contract faced higher-than-expected service costs from utilization and hospital-ordering issues.

Published Aug 11Source: Yahoo Finance ↗

BioLive Wire · AI-collected

Hims & Hers Raises Annual Revenue Forecast on Strong Subscriber Growth

Hims & Hers raised its annual revenue forecast, citing strong subscriber growth, according to an Investing.com report.

Published Aug 10Source: Investing.com ↗

BioLive Wire · AI-collected

Eli Lilly's Weight-Loss Pill Secures First European Nod in Britain

Eli Lilly's weight-loss pill secured its first European regulatory approval in Britain, according to an Investing.com report.

Published Aug 10Source: Investing.com ↗

BioLive Wire · AI-collected

Latigo Biotherapeutics Shares Jump 17% After Upsized IPO

Latigo Biotherapeutics shares jumped 17% after the company's upsized IPO, according to a report.

Published Aug 7Source: Investing.com ↗

BioLive Wire · AI-collected

Oxford Biomedica Cuts 2026 Revenue Guidance by 17%

Oxford Biomedica cut its 2026 revenue guidance by 17%, according to a report.

Published Aug 7Source: Investing.com ↗

BioLive Wire · AI-collected

Gedeon Richter Upgrades FY26 Profit Guidance on Vraylar Strength

Gedeon Richter upgraded its FY26 profit guidance, citing strength in Vraylar, according to a report.

Published Aug 7Source: Investing.com ↗